Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21491326 | 0.89 | CYP3A4 (0.43) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1680605 | 0.84 | TSHR (0.32) | TSHRADRB2ADRB1ADRB3 | |
| SCHEMBL1680269 | 0.84 | TSHR (0.42) | MEN1KMT2AALDH1A1TSHRCYP3A4 | |
| SCHEMBL4881159 | 0.81 | TSHR (0.33) | TSHR | |
| SCHEMBL28500589 | 0.80 | CYP3A4 (0.40) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6697084 | 0.80 | ALDH1A1 (0.33) | MEN1KMT2AALDH1A1TSHRCYP3A4 | |
| SCHEMBL31515197 | 0.78 | TSHR (0.54) | MEN1KMT2AALDH1A1TSHRCYP3A4 | |
| SCHEMBL3151320 | 0.78 | CYP3A4 (0.33) | MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL509694 | 0.77 | LMNA (0.30) | TSHR | |
| SCHEMBL3147839 | 0.75 | DNM1 (0.38) | DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705292-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4700025-A1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Suzhou Genhouse Bio Co., Ltd. (CN) | 2026-02-25 | — | — | EP | disclosed |
| EP-4676480-A1 | INHIBITORS OF DNA POLYMERASE THETA | Breakpoint Therapeutics GmbH (DE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| EP-4673136-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | Vanderbilt University (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4638447-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3947366-A1 | HPK1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2022-02-09 | — | — | EP | disclosed |
| EP-3946618-A1 | METTL3 INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| CN-110799509-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| EP-3541813-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-09-25 | — | — | EP | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
| WO-2018092089-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | DNM1 3762/4885MEN1 1195/4885KMT2A 110/4885 |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | DNM1 1116/4885MEN1 1022/4885KMT2A 1628/4885 |
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | DNM1 3876/4885MEN1 1705/4885KMT2A 474/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | DNM1 3415/4885MEN1 3248/4885KMT2A 534/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | DNM1 3050/4885MEN1 3035/4885KMT2A 1216/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | DNM1 1116/4885MEN1 1022/4885KMT2A 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.